Quantisnow Logo
Dashboard

Director Xu Yuan sold $2,678 worth of shares (633 units at $4.23), decreasing direct ownership by 7% to 8,669 units (SEC Form 4)

$FATE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $FATE alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Get startedLearn more

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

Get startedLearn more
App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $FATE alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$FATE

DatePrice TargetRatingAnalyst
11/18/2024Underperform → Neutral
BofA Securities
6/17/2024$4.00 → $6.00Neutral → Overweight
Piper Sandler
3/27/2023$6.00Equal Weight
Wells Fargo
1/24/2023$115.00 → $7.00Buy → Neutral
H.C. Wainwright
1/6/2023$20.00 → $7.00Outperform → Market Perform
BMO Capital Markets
1/6/2023$71.00 → $12.00Overweight → Neutral
Piper Sandler
1/6/2023Outperform → Market Perform
Cowen
1/6/2023$107.00 → $5.30Buy → Hold
Stifel
More analyst ratings

$FATE
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

    Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe SLE Completed Type D Meeting with FDA to Enable FT819 Off-the-Shelf CAR T-cell Dose Expansion in Additional B Cell-mediated Autoimmune Diseases First FT819 Off-the-Shelf CAR T-cell Patient Treated without Conditioning Chemotherapy as Add-on to Maintenance Therapy in SLE $307 Million in Cash, Cash Equivalents and Investments with Projected Operating Runway through YE26 SAN DIEGO, March 05, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced

    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on March 3, 2025 the Company granted restricted stock units (RSUs) representing 24,000 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering in

    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Fate Therapeutics to Present at Upcoming Investor Conferences

    SAN DIEGO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences: H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference, including a fireside chat at 1:30 PM ET on Tuesday, February 25, 2025TD Cowen 45th Annual Health Care Conference, including a company presentation at 11:50 AM ET on Monday, March 3, 2025 in Boston, MassachusettsBarclays 27th Annual Global Hea

    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$FATE
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$FATE
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$FATE
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$FATE
 SEC Filings

See more

$FATE
 Leadership Updates

Live Leadership Updates

See more

  • Fate Therapeutics Announces Leadership Transition

    Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025 Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies SAN DIEGO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE) ("Fate Therapeutics" or the "Company"), a clinical-stage biopharmaceutical company dedicated to bringing first-in-class induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that Scott Wolchko, the Company's President and CEO, will retire effective December 31, 2024. Fate's current President of Research and Development (R&D), Bob Vala

    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors

    SAN DIEGO, July 31, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced the appointment of Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors effective immediately. Dr. Mozaffarian brings to the Company medical and scientific leadership in the field of immunology and autoimmunity, with over 20 years of research and industry experience in the discovery, development, and commercialization of novel small and large molecule therapeutics. "Dr. Moza

    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Radionetics Oncology Raises $52.5 Million Series A to Advance First-in-Class Radiopharmaceutical Pipeline and Announces the Appointment of Industry Leader, Paul Grayson, as CEO

    - Series A led by Frazier Life Sciences, 5AM Ventures and DCVC Bio, bringing total raised to date to $82.5 million - Paul Grayson joins as Chief Executive Officer, bringing additional expertise in business strategy, oncology, and G-protein coupled receptor biology - Radionetics expands board of directors with the appointment of Eric Shiozaki, Ph.D., Partner at DCVC Bio Radionetics Oncology, Inc., a clinical stage radiopharmaceutical company focused on the discovery and development of novel agents for the treatment of a wide range of oncology indications, announces the completion of a $52.5 million Series A financing. The round was led by Frazier Life Sciences, 5AM Ventures, and new invest

    $CRNX
    $FATE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

$FATE
 Financials

Live finance-specific insights

See more

  • Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

    First Lupus Patient Treated with FT819 CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Future Clinical Development of FT819 to Focus Exclusively on Autoimmune Disease Enrollment Initiated with FT522 CAR NK Cell Product Candidate in Conditioning-free Treatment Arm of Phase 1 B Cell Lymphoma Study First Patient Treated with FT825 / ONO-8250 CAR T-cell Product Candidate in Phase 1 Solid Tumor Study $391 Million in Cash, Cash Equivalents, and Investments SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPS

    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates

    SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, will host a conference call and live audio webcast on Thursday, May 9, 2024 at 5:00 PM ET to report its first quarter 2024 financial results and highlight operational updates, including a review of its FT819 and FT522 programs for autoimmune diseases being featured on the same day at the American Society of Gene and Cell Therapy 27th Annual Meeting. In order

    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

    CIRM Grant Awarded to Support Phase 1 Autoimmunity Study of FT819 CD19-targeted CAR T-cell Program for Systemic Lupus Erythematosus; Study Start-up Ongoing at Multiple Clinical Sites First Patient Treated in Phase 1 Study of FT522 ADR-armed, CD19-targeted CAR NK Cell Program; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Chemotherapy Conditioning Phase 1 Study Initiated of FT825 / ONO-8250 CAR T-cell Program for Solid Tumors; Incorporates Seven Synthetic Controls including Novel Cancer-specific CAR Targeting HER2 $316 Million in Cash, Cash Equivalents, and Investments SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FA

    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$FATE
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more